| Literature DB >> 28981328 |
Abstract
Historically, HER2-positive breast cancer had a poor prognosis. The development of molecul ar ther apies that target the HER2 receptor has TR ansformed outcomes. Here, the evidence on Anti-HER2 therapies is summarised.Entities:
Mesh：
Substances：
Year: 2017 PMID： 28981328 DOI： 10.12968/bjon.2017.26.Sup16a.S7
Source DB: PubMed Journal: Br J Nurs ISSN： 0966-0461